Plasma potassium in hypertensive Africans on frusemide

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Hypertension is a prevalent condition, often managed with diuretics like frusemide.
• Frusemide can lead to potassium depletion, necessitating monitoring and management.
• African populations may exhibit unique responses to antihypertensive therapies.

Purpose of the Study:

• To compare the efficacy of potassium chloride (Slow-K) and spironolactone (Aldactone A) in hypertensive patients receiving frusemide.
• To evaluate the impact of these interventions on plasma-potassium levels.
• To assess the effects on both systolic and diastolic blood pressure.

Main Methods:

• A comparative study involving hypertensive African patients on frusemide.
• Administration of potassium chloride (Slow-K 600 mg TID) or spironolactone (Aldactone A 25 mg QID).
• Monitoring of mean plasma-potassium levels and mean blood pressure (systolic and diastolic).

Main Results:

• Plasma-potassium levels increased from 3.6 to 3.8 mOsm/L with both frusemide plus Slow-K and frusemide plus Aldactone-A.
• Plasma-potassium levels fell from 3.7 to 3.6 mOsm/L in patients on frusemide alone.
• A significant reduction in both systolic and diastolic blood pressure was observed in the frusemide plus Aldactone-A group compared to frusemide alone or frusemide plus Slow-K.

Conclusions:

• Spironolactone (Aldactone A) demonstrates superior efficacy in reducing blood pressure in hypertensive patients on frusemide compared to potassium chloride (Slow-K).
• Both spironolactone and potassium chloride help maintain plasma-potassium levels in patients on frusemide.
• Spironolactone is a valuable therapeutic option for managing hypertension in patients receiving frusemide, particularly for blood pressure control.